MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages 530-535

  Zhao, Qingguo ^a   Gregory, Carl A ^a   Lee, Ryang Hwa ^a   Reger, Roxanne L ^a   Qin, Lizheng ^a   Hai, Bo ^a   Park, Min Sung ^a   Yoon, Nara ^a   Clough, Bret ^a   McNeill, Eoin ^a   Prockop, Darwin J ^a   Liu, Fei ^a  

^a Texas Agricultural and Mechanical   (United States)

Author keywords

Cancer; IPS cells; Mesenchymal stem cells; Protumor effects; Tumor tropism

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD11B ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; ENDOGLIN; FIBRONECTIN; FIBRONECTIN 1; GELATINASE A; HEPATOCYTE NUCLEAR FACTOR 3BETA; HERMES ANTIGEN; HLA DR ANTIGEN; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR 1; VIMENTIN;

ADHERENT CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER STEM CELL; CELL AGING; CELL DIFFERENTIATION; CELL HOMING; CELL INVASION; CELL SELECTION; COCULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOPLASM; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL EXPANSION; TERATOMA; TROPISM; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CELL MOTION; CYTOLOGY; FEMALE; MESENCHYMAL STROMA CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HETEROGRAFTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS;

EID: 84920982994     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423008112     Document Type: Article

References (50)

1. Droujinine IA, Eckert MA, Zhao W (2013) To grab the stroma by the horns: From biology to cancer therapy with mesenchymal stem cells. Oncotarget 4(5):651-664.
2. Zimmerlin L, Park TS, Zambidis ET, Donnenberg VS, Donnenberg AD (2013) Mesenchymal stem cell secretome and regenerative therapy after cancer. Bio chimie 95(12): 2235-2245.
3. Chaturvedi P, et al.; Kshitiz (2013) Hypoxia-inducible factor-dependent breast cancermesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 123(1):189-205.
4. Quante M, et al. (2011) Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19(2):257-272.
5. Song C, Li G (2011) CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy 13(5):549-561.
6. Jung Y, et al. (2013) Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 4:1795.
7. Lee JH, et al. (2012) Dental follicle cells and cementoblasts induce apoptosis of ameloblast- lineage and Hertwig's epithelial root sheath/epithelial rests of Malassez cells through the Fas-Fas ligand pathway. Eur J Oral Sci 120(1):29-37.
8. Loebinger MR, Eddaoudi A, Davies D, Janes SM (2009) Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69(10):4134-4142.
9. Grisendi G, et al. (2010) Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 70(9):3718-3729.
10. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309):71-74.
11. Pittenger MF, et al. (1999) Multi lineage potential of adult human mesenchymal stem cells. Science 284(5411):143-147.
12. Meirelles LdaS, Fontes AM, Covas DT, Caplan AI (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20(5- 6):419-427.
13. Donnenberg VS, Zimmerlin L, Rubin JP, Donnenberg AD (2010) Regenerative therapy after cancer: What are the risks? Tissue Eng Part B Rev 16(6):567-575.
14. Lin CY, et al. (2011) Cell therapy for salivary gland regeneration. J Dent Res 90(3): 341-346.
15. Sumita Y, et al. (2011) Bone marrow-derived cells rescue salivary gland function in mice with head and neck irradiation. Int J Biochem Cell Biol 43(1):80-87.
16. Fritz V, et al. (2008) Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Stem Cells 26(11):2981-2990.
17. Li X, et al. (2011) Human placenta-derived adherenT cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells 29(2): 263-273.
18. Karnoub AE, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557-563.
19. Li HJ, Reinhardt F, Herschman HR, Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2(9):840-855.
20. Liu S, et al. (2011) Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71(2):614-624.
21. Barkholt L, et al. (2013) Risk of tumorigenicity in mesenchymal stromal cell-based therapies: Bridging scientific observations and regulatory viewpoints. Cytotherapy 15(7):753-759.
22. Gu J, et al. (2012) Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS ONE 7(12):e52465.
23. Klopp AH, et al. (2012) Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 18(3):771-782.
24. Kidd S, et al. (2012) Origins of the tumor microenvironment: Quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE 7(2):e30563.
25. Larson BL, Ylostalo J, Lee RH, Gregory C, Prockop DJ (2010) Sox11 is expressed in early progenitor human multi potent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A 16(11):3385-3394.
26. Viswanathan S, et al. (2014) Soliciting strategies for developing cell-based reference materials to advance MSC research and clinical translation. Stem Cells Dev 23(11): 1157-1167.
27. Sánchez L, et al. (2011) Enrichment of human ESC-derived multi potent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells 29(2):251-262.
28. Ludwig TE, et al. (2006) Feeder-independent culture of human embryonic stem cells. Nat Methods 3(8):637-646.
29. Olivier EN, Bouhassira EE (2011) Differentiation of human embryonic stem cells into mesenchymal stem cells by the "raclure" method. Methods Mol Biol 690:183-193.
30. Lai RC, Choo A, Lim SK (2011) Derivation and characterization of human ESC-derived mesenchymal stem cells. Methods Mol Biol 698:141-150.
31. Lian Q, et al. (2007) Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells 25(2):425-436.
32. Dominici M, et al. (2006) Minimal criteria for defining multi potent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-317.
33. Spaeth EL, et al. (2013) Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res 73(17):5347-5359.
34. Lee RH, et al. (2009) The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113(4):816-826.
35. Ip JE, et al. (2007) Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 18(8):2873-2882.
36. Cioce M, et al. (2010) Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle 9(14):2878-2887.
37. Sims JE, et al. (1993) Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 90(13):6155-6159.
38. Shangguan L, et al. (2012) Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 30(12):2810-2819.
39. Hogan NM, et al. (2013) Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation. Bio chem Biophys Res Commun 435(4): 574-579.
40. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA (2003) Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162(2):533-546.
41. Boehm JR, Kutz SM, Sage EH, Staiano-Coico L, Higgins PJ (1999) Growth state dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor-beta1. J Cell Physiol 181(1):96-106.
42. El-Haibi CP, et al. (2012) Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA 109(43):17460-17465.
43. Lee RH, et al. (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5(1):54-63.
44. Lesley J, et al. (2004) TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem 279(24):25745-25754.
45. Ramsey WS, Hertl W, Nowlan ED, Binkowski NJ (1984) Surface treatments and cell attachment. In Vitro 20(10):802-808.
46. Prockop DJ, Keating A (2012) Relearning the lessons of genomic stability of human cells during expansion in culture: Implications for clinical research. Stem Cells 30(6): 1051-1052.
47. de Peppo GM, et al. (2013) Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc Natl Acad Sci USA 110(21):8680-8685.
48. Zou J, et al. (2011) Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: Functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 117(21):5561-5572.
49. Hai B, et al. (2010) Wnt/β-catenin signaling regulates postnatal development and regeneration of the salivary gland. Stem Cells Dev 19(11):1793-1801.
50. Moulay G, Boutin S, Masurier C, Scherman D, Kichler A (2010) Polymers for improving the in vivo transduction efficiency of AAV2 vectors. PLoS One 5(12):e15576.